What BASF’s collagen hybridizing peptide ingredient is designed to do

BASF’s collagen hybridizing peptide research reached the IFSCC Congress in Perth as poster 283, “Advanced Design of BioActive Collagen Hybridizing Peptides to Target and Repair Damaged Collagen.” The presentation followed the April 2026 launch of NeoHelix Regenerate, a cosmetic active BASF developed through its partnership with Utah biotechnology company 3Helix. The Congress news is therefore a closer look at an ingredient already being offered to personal-care formulators.

The ingredient’s appeal starts with the unusual targeting concept. Classical collagen hybridizing peptides, or CHPs, are synthetic strands that recognize unfolded collagen and can form a hybrid triple helix with it. A PubMed Central review of CHP research describes the technology chiefly as a research tool for detecting collagen damage and remodeling. 3Helix continues to sell labelled CHP products for histopathology applications, including fibrosis, inflammatory injury and mechanically damaged tissue. BASF is applying that recognition principle to topical skin care.

That application rests on a plausible skin-aging hypothesis. Fragmented collagen accumulates in photoaged skin, and fibroblasts can lose mechanical contact with the surrounding extracellular matrix. Research indexed by PubMed links this altered matrix environment with lower procollagen production and greater expression of collagen-degrading enzymes. BASF says NeoHelix is engineered to bind damaged collagen and support fibroblast and extracellular-matrix signaling. Binding a damaged target does not by itself show that a topical peptide reaches dermal collagen at an effective dose or changes tissue structure in people.

The wording around the material matters. BASF’s April launch release says NeoHelix “adapts concepts from” 3Helix CHP technology, while its product materials describe an ingredient “adapted from” that technology. Those phrases leave open whether NeoHelix is a conventional CHP that forms a hybrid triple helix with denatured collagen, a modified bioactive peptide, or a wider ingredient system. Its INCI identity and the underlying peptide architecture would help formulators understand compatibility, stability and the relevance of the CHP mechanism in a finished emulsion or serum.

BASF reports that a 56-day biopsy-based clinical assessment found 41% less damaged collagen and 65% more hyaluronic acid. It also says NeoHelix, used at 1%, outperformed an unnamed peptide benchmark used at 3% for wrinkle depth and skin thickness. Concentration alone cannot settle that comparison: peptide identity, vehicle, delivery, study design and measurement method can each alter the result. BASF’s public product page does not give participant numbers, skin demographics, randomization, vehicle controls, biopsy method, statistical outcomes, adverse events or the NeoHelix concentration used in the biopsy study.

For brands considering the ingredient, the distinction between an active’s test package and a retail formula is consequential. A finished product may use a different level, vehicle, preservation system, pH range and application routine from BASF’s evaluated prototype. The most useful next disclosure would be the assay behind “damaged collagen,” plus evidence of where the peptide localizes after topical application. Until then, the most concrete public scientific marker is BASF’s IFSCC poster 283, “Advanced Design of BioActive Collagen Hybridizing Peptides to Target and Repair Damaged Collagen.”